Recent Finacing
Recent Raise
CoRegen develops adoptive regulatory T‑cell therapies engineered with SRC‑3 knockout to modulate immune‑checkpoint networks for treatment of difficult solid tumors such as triple‑negative breast cancer and glioblastoma.
Focus Areas
Total Raised
Funding round
See the team members at CoRegen.
